Lin Q - Search Results

1

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.

Lin Q, Chen X, Qu L, Guo M, Wei H, Dai S, Jiang L, Chen Y. Lin Q, et al. Commun Chem. 2022 Aug 22;5(1):100. doi: 10.1038/s42004-022-00718-z. Commun Chem. 2022. PMID: 36698015 Free PMC article.

2

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

Shao M, Chen X, Yang F, Song X, Zhou Y, Lin Q, Fu Y, Ortega R, Lin X, Tu Z, Patterson AV, Smaill JB, Chen Y, Lu X. Shao M, et al. Among authors: lin q, lin x. J Med Chem. 2022 Mar 24;65(6):5113-5133. doi: 10.1021/acs.jmedchem.2c00096. Epub 2022 Mar 10. J Med Chem. 2022. PMID: 35271262

3

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects.

Lin Q, Xia X, Li J, Zhou Z, Chen Y. Lin Q, et al. Eur J Med Chem. 2022 Nov 15;242:114672. doi: 10.1016/j.ejmech.2022.114672. Epub 2022 Aug 10. Eur J Med Chem. 2022. PMID: 35973313

4

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.

Wang C, Li J, Qu L, Tang X, Song X, Yang F, Chen X, Lin Q, Lin W, Zhou Y, Tu Z, Chen Y, Zhang Z, Lu X. Wang C, et al. Among authors: lin q, lin w. J Med Chem. 2022 Nov 24;65(22):15140-15164. doi: 10.1021/acs.jmedchem.2c00981. Epub 2022 Nov 10. J Med Chem. 2022. PMID: 36355693

5

Structure-based design of a dual-warhead covalent inhibitor of FGFR4.

Chen X, Li H, Lin Q, Dai S, Yue S, Qu L, Li M, Guo M, Wei H, Li J, Jiang L, Xu G, Chen Y. Chen X, et al. Among authors: lin q. Commun Chem. 2022 Mar 17;5(1):36. doi: 10.1038/s42004-022-00657-9. Commun Chem. 2022. PMID: 36697897 Free PMC article.

6

Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R.

Lin Q, Dai S, Qu L, Lin H, Guo M, Wei H, Chen Y, Chen X. Lin Q, et al. Among authors: lin h. Commun Chem. 2024 Jan 3;7(1):3. doi: 10.1038/s42004-023-01084-0. Commun Chem. 2024. PMID: 38172256 Free PMC article.

7

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

Yang F, Lin Q, Song X, Huang H, Chen X, Tan J, Li Y, Zhou Y, Tu Z, Du H, Zhang ZM, Ortega R, Lin X, Patterson AV, Smaill JB, Chen Y, Lu X. Yang F, et al. Among authors: lin q, lin x. J Med Chem. 2024 Feb 22;67(4):2667-2689. doi: 10.1021/acs.jmedchem.3c01810. Epub 2024 Feb 13. J Med Chem. 2024. PMID: 38348819

8

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.

Chen X, Li H, Lin Q, Dai S, Qu L, Guo M, Zhang L, Liao J, Wei H, Xu G, Jiang L, Chen Y. Chen X, et al. Among authors: lin q. Eur J Med Chem. 2024 Mar 15;268:116281. doi: 10.1016/j.ejmech.2024.116281. Epub 2024 Feb 28. Eur J Med Chem. 2024. PMID: 38432058

9

An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.

Xia X, Lin Q, Zhou Z, Chen Y. Xia X, et al. Among authors: lin q. iScience. 2024 Mar 1;27(4):109377. doi: 10.1016/j.isci.2024.109377. eCollection 2024 Apr 19. iScience. 2024. PMID: 38510128 Free PMC article.

10

Strong Homology Between Colonizing and Bloodstream Carbapenem-Resistant Acinetobacter Spp.: Implications for Empiric Antibiotic Therapy in Hematological Patients.

Li J, Guo W, Wang J, Feng X, Lin Q, Zheng Y, Zhang F, Mi Y, Zhu X, Jiang E, Xiao Z, Wang J, Feng S. Li J, et al. Among authors: lin q. Infect Drug Resist. 2024 May 9;17:1827-1838. doi: 10.2147/IDR.S458427. eCollection 2024. Infect Drug Resist. 2024. PMID: 38741942 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8,653 results

Search Page